Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
0.600
0.00 (0.00%)
At close: Jan 17, 2025, 4:00 PM
0.610
+0.010 (1.67%)
After-hours: Jan 17, 2025, 4:59 PM EST
Passage Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Passage Bio stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 13. The average target predicts an increase of 1,233.33% from the current stock price of 0.60.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 29, 2024.
Analyst Ratings
The average analyst rating for Passage Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $4 | Buy | Initiates | $4 | +566.67% | Nov 29, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +1,066.67% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +2,066.67% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +2,066.67% | Sep 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +2,066.67% | May 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.97
from -1.86
EPS Next Year
-0.67
from -0.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 1.7M | |||
| Avg | n/a | n/a | 408,000 | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.57 | -0.29 | -0.28 | |||
| Avg | -0.97 | -0.67 | -0.76 | |||
| Low | -1.09 | -0.98 | -1.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.